[1] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[2] Chen W, Zheng R, Zuo T, et al.National cancer incidence and mortality in China, 2012[J]. Chin J Cancer Res,2016,28(1):1-11.
[3] Yu W, Whang I, Chung HY, et al.Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial[J]. World J Surg,2001,25(8):985-990.
[4] Fujimoto S, Takahashi M, Mutou T, et al.Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery[J]. Cancer,1997, 79(5):884-891.
[5] Hirose K, Katayama K, Iida A, et al.Efficacy of conti-nuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis[J]. Oncology,1999,57(2):106-114.
[6] Yonemura Y, Kawamura T, Bandou E, et al.Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion[J]. Br J Surg,2005,92(3):370-375.
[7] Glehen O, Schreiber V, Cotte E, et al.Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer[J]. Arch Surg,2004,139(1):20-26.
[8] Li C, Yan M, Chen J, et al.Surgical resection with hyperthermic intraperitoneal chemotherapy for gastric cancer patients with peritoneal dissemination[J]. J Surg Oncol,2010,102(5):361-365.
[9] Gill RS, Al-Adra DP, Nagendran J, et al.Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity[J]. J Surg Oncol,2011, 104(6):692-698.
[10] Yang XJ, Huang CQ, Suo T, et al.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase Ⅲ randomized clinical trial[J]. Ann Surg Oncol,2011,18(6):1575-1581.
[11] Yuan M, Wang Z, Hu G, et al.A retrospective analysis of hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis[J]. Mol Clin Oncol,2016, 5(2):395-399.
[12] Facchiano E, Risio D, Kianmanesh R, et al.Laparoscopic hyperthermic intraperitoneal chemotherapy: indications, aims, and results: a systematic review of the literature[J]. Ann Surg Oncol,2012,19(9):2946-2950.
[13] Randle RW, Swett KR, Swords DS, et al.Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites[J]. Ann Surg Oncol,2014,21(5):1474-1479.
[14] Roviello F, Caruso S, Neri A, et al.Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale[J]. Eur J Surg Oncol,2013,39(12):1309-1316.
[15] Seshadri RA, Glehen O.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer[J]. World J Gastroenterol,2016,22(3):1114-1130.
[16] Polom K, Marano L, Roviello G, et al.Evolution and emerging future of cytoreducxtive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence[J]. Int J Hyperthermia,2016,32(2):173-179.
[17] Zhu ZG, Tang R, Yan M, et al.Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study[J]. Dig Surg,2006,23(1-2):93-102.
[18] Sun J, Song Y, Wang Z, et al.Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the rando-mized controlled trials[J]. BMC Cancer,2012,12:526.
[19] Mi DH, Li Z, Yang KH, et al.Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials[J]. Int J Hyperthermia,2013,29(2):156-167.
[20] Coccolini F, Cotte E, Glehen O, et al.Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials[J]. Eur J Surg Oncol,2014,40(1):12-26.
[21] 倪震天, 李琛, 严超, 等. 手术联合术中腹腔温热化疗治疗进展期胃癌的疗效及安全性的Meta分析[J]. 中华胃肠外科杂志,2016,19(12):1406-1413.
[22] Fujimura T, Yonemura Y, Nakagawara H, et al.Subtotal peritonectomy with chemohyperthermic peritoneal perfusion for peritonitis carcinomatosa in gastrointestinal cancer[J]. Oncol Rep,2000,7(4):809-814.
[23] Rudloff U, Langan RC, Mullinax JE, et al.Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy(HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial[J]. J Surg Oncol,2014,110(3):275-284.
[24] Mohamed F, Moran BJ.Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve[J]. Cancer J,2009,15(3):196-199.
[25] Pascual-Ramírez J, Sánchez García S, González Ruiz de la Herrán F, et al. Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs[J]. Arch Gynecol Obstet,2014,290(1):121-129.
[26] Raspe C, Piso P, Wiesenack C, et al.Anesthetic management in patients undergoing hyperthermic chemotherapy[J]. Curr Opin Anaesthesiol,2012,25(3):348-355.
[27] Morris DL, Chambers HF, Morris MG, et al.Hemodynamic characteristics of patients with hypothermia due to occult infection and other causes[J]. Ann Intern Med,1985,102(2):153-157.
[28] Passot G, Bakrin N, Isaac S, et al.Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies[J]. Eur J Surg Oncol,2014,40(8):957-962.
[29] Putzu M, Casati A, Berti M, et al.Clinical complications, monitoring and management of perioperative mild hypothermia: anesthesiological features[J]. Acta Biomed,2007,78(3):163-169.
[30] Scott EM, Buckland R. A systematic review of intraoperative warming to prevent postoperative complications[J]. AORN J,2006,83(5):1090-1104, 1107-1113.
[31] Stuart OA, Stephens AD, Welch L, et al.Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C[J]. Ann Surg Oncol,2002,9(2):186-191.
[32] Schmid K, Boettcher MI, Pelz JO, et al.Investigations on safety of hyperthermic intraoperative intraperitoneal chemo-therapy (HIPEC) with Mitomycin C[J]. Eur J Surg Oncol,2006,32(10):1222-1225.
[33] Guerbet M, Goullé JP, Lubrano J.Evaluation of the risk of contamination of surgical personnel by vaporization of oxaliplatin during the intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)[J]. Eur J Surg Oncol,2007,33(5):623-626.
[34] Konate A, Poupon J, Villa A, et al.Evaluation of environmental contamination by platinum and exposure risks for healthcare workers during a heated intraperitoneal perioperative chemotherapy (HIPEC) procedure[J]. J Surg Oncol,2011,103(1):6-9.
[35] Bharali DJ, Mousa SA.Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise[J]. Pharmacol Ther,2010, 128(2):324-335.
[36] Matano D, Moriwaki T, Tange Y, et al.Successful long-term management with a single administration of tri-weekly nab-paclitaxel in a patient with advanced gastric cancer with peritoneal dissemination[J]. Intern Med,2017, 56(8):921-923.
[37] Frank D, Tyagi C, Tomar L, et al.Overview of the role of nanotechnological innovations in the detection and treatment of solid tumors[J]. Int J Nanomedicine,2014,9:589-613.
[38] Wong BS, Yoong SL, Jagusiak A, et al.Carbon nanotubes for delivery of small molecule drugs[J]. Adv Drug Deliv Rev,2013,65(15):1964-2015.
